Scientists are exploring if early intervention can prevent AML in high-risk patients, shifting the focus from monitoring to proactive prevention.
CAMBRIDGE, Mass., July 10, 2025 /PRNewswire/ -- Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to evaluate the feasibility of early intervention for Clonal Hematopoiesis (CH), a precursor to acute myeloid leukemia (AML). This multi-institutional study focuses on high-risk patients, exploring a new approac